Revlon, Inc. to Settle Charges of Unsubstantiated Ad Claims
for "Anti-Cellulite" and Sunscreen Products

FTC News Release
August 24, 1993

Revlon, Inc., and its subsidiary, Charles Revson, Inc., have agreed to settle Federal Trade Commission charges of unsubstantiated advertising claims for their Ultima II Pro-Collagen Anti-cellulite body complex ("Anti-cellulite body complex") and PhotoAging Shield ("PAS") products. A proposed consent agreement would require competent and reliable scientific evidence to substantiate such claims in the future.

Revlon, Inc., is a Delaware corporation and Charles Revson, Inc., is a New York corporation, both with headquarters in New York City.

According to the complaint attached to the agreement, through statements and depictions in advertising and promotional materials, Revlon claimed that its ProCollagen body complex:

The complaint charges Revlon with representing that it had a reasonable basis for such claims when, in fact, it did not.

In addition, according to the FTC, Revlon marketed PAS as a product intended to prevent "photoaging." Photoaging occurs when the ultraviolet rays (UV) from natural sunlight, and possibly from artificial light, cause the skin to become prematurely wrinkled and leathery. According to the Commission's complaint, Revlon advertising and promotional materials for PAS contained the following claims:

The FTC alleged that these and other statements and depictions in advertisements and promotional materials have represented that PAS blocks all of the harmful rays which cause photoaging. The complaint alleges that Revlon falsely represented that it had a reasonable basis for such a claim.

The proposed consent agreement to settle these charges, announced today for public comment, would require Revlon to have scientific evidence to support any future claims about the effectiveness of cellulite treatments or sunscreen products. Revlon also would be required to disclose the sun protection factor (SPF) value in any sunscreen ad in which it touts the ability of the product to protect against the sun's rays.

The order also would permit representations for sunscreen products that the Food and Drug Administration (FDA) establishes as supported by scientific evidence in a tentative final or final standard. FDA issued a tentative final monograph on over-the-counter sunscreen drug products on May 12, 1993.

The Commission vote to amend the complaint and accept the proposed consent agreement for public comment was 5-0.

A fact sheet on sunscreen products and the type of protection they offer is available from the FTC.

Related Documents

This page was posted on August 27, 2006.

Links to Recommended Companies